News und Analysen

Lyon, France – 25 April 2022 – 7:00 am CEST –Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating

(Unaudited data)

Quantum Genomics Announces Publication of a New Scientific Article Featuring QGC606

Quantum Genomics (Euronext Growth : ALQGC, OTCQX : QNNTF), a biopharmaceutical company specializing in the

Quantum Genomics Announces Granting of New Patents Protecting QGC606

Quantum Genomics (Euronext Growth : ALQGC, OTCQX : QNNTF), a biopharmaceutical company specializing in the development of a new

Stéphane Cohen joins Quantum Genomics as Director of Global Operations

Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC), a biopharmaceutical company specializing in the development of a new

The Board of Directors of BOIRON, at its meeting on March 9, 2022 chaired by Thierry Boiron, made up the statutory and consolidated financial statements of the financial year ended on December 31

• · New milestone for NeuroLead, the active agent screening platform
• · New publications in scientific journals
• · Start of Phase I/II clinical trial for Batten disease

Lyon, 28 February 2022

Lyon, France – Austin, TX, USA - 3 February 2022 – Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates

(Unaudited data)

QUARTERLY ACTIVITY IN 2021 (VARIATION AT CURRENT EXCHANGE RATES)

Lyon, 13 January 2022 – Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating the interaction

Lyon, December 20, 2021 – Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating the interaction

Press release

Paris, December 6, 2021

Quantum Genomics signs an exclusive license and production agreement with Gulf Pharmaceuticals Industries Julphar.

• Quantum Genomics will receive up to $20 M

Nearly 90% of international nurses providing care in the United States have treated COVID-19 patients, while 17% have themselves contracted the coronavirus, according to a new survey.

Conducted

DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the following upcoming investor conference:

• 
  Jereme Sylvain, Executive Vice President and Chief

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and DiaSorin (FTSE MIB: DIA) today announced that the U.S. Food and Drug Administration (FDA) has approved the LIAISON^® QuantiFERON^®-TB Gold Plus